MACE
12
2
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
Tezspire Cardiac Events PASS
AI-Based Risk Factor Analysis and Prediction Model of MACE in Elderly Hip Fracture Patients Postoperatively
Real-World Cohort Study of Cardiopulmonary Function in Chinese Patients With Cardiovascular Disease: CPET Evaluation and Five-Year Prognostic Follow-Up Based on a Multicenter Structured Data Platform
throMboembolic Risk Associated To High atrIal Fibrillation riSk
Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?
Steroid Treatment to Prevent Thoracic Endovascular Aortic Repair Postimplantation Syndrome
Prospective Observational Cohort Study on Impact of Frailty on Risk Prediction, Treatment Strategies, and Short-Term Outcomes in Patients With Acute Coronary Syndrome
"Short-term Outcome in STEMI Patients Undergoing Primary PCI: A Comparative Study Between Rural and Urban Communities at Assiut University."
Primary Prevention Long-term Registry Study in OSA and Hypertension. Survival Analysis 2010-2022
Discharge Planning Program for Post CABG Patients
ROOBY Trial Follow-up Extension
The Prognostic Significance of a Fragmented QRS Complex After Primary Percutaneous Coronary Intervention